BSEBeryl Drugs LtdMediumNeutral
Announced Tue, 30 Sept · 14:20 IST

OUTCOME OF 32ND ANNUAL GENERAL MEETING OF THE COMPANY HELD ON 30TH SEPTEMBER, 2025

Management Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Beryl Drugs held its 32nd AGM on 30th September 2025 at Kanchan Palace, Indore, from 11:00 AM to 2:15 PM. Shareholders approved the reappointment of Mr. Sudhir Sethi (DIN: 00090172) as a Director for a further period of five years. They also approved the reappointment of Mr. Sanjay Sethi (DIN: 00090277) as Managing Director, now designated as Executive Director, for another five-year term. The document does not disclose voting percentages or financial results. Both appointees are from the Sethi family, indicating continued family control of the company.

Likely market impact

These are routine reappointments with no change in leadership, so the impact on shareholders is neutral. Investors should note the continuation of the promoter family in key board positions, which means no fresh governance overhaul.